Impact of duration of treatments with metformin and sulfonylureas, individually or in combination, on diabetic retinopathy among newly diagnosed type 2 diabetic patients: a pooled cohort’s analysis
International Journal of Retina and Vitreous,
Год журнала:
2025,
Номер
11(1)
Опубликована: Янв. 31, 2025
This
study
aimed
to
evaluate
the
effect
of
metformin
and
sulfonylurea
(SUs)
medication
time
on
Diabetic
retinopathy
(DR)
among
newly
diagnosed
patients
with
type
2
diabetes
(T2DM)
using
a
pooled
analysis.
SUs'
DR
T2DM
The
data
4,068
DM
individuals(mean
age,
60.2
±
0.85
years)
from
three
prospective
cohorts
Tehran
Sugar
Lipid
Study
(TLGS),
Multi-Ethnic
Atherosclerosis
(MESA),
Risk
in
Communities
(ARIC)
mean
age
59.6
08
years
were
pooled.
cumulative
exposure
metformin,
SUs,
aspirin,
statin,
anti-hypertensive
was
also
determined
same
approach.
Cox
proportional
hazards
(CPH)
model
used
calculate
hazard
ratio
(HR)
(95%
CI)
for
outcomes
while
adjusting
confounding
factors
such
as
fasting
Blood
(FBS),
medications.
During
follow-up,
occurred
519
DM.
Metformin
alone,
SUs
combination
both
reduced
by
10%,
7%,
11%
each
year
use,
respectively
(p
<
0.05).
protective
individually
or
combination,
started
approximately
five
after
initial
treatment
continued
until
15
then
reached
plato.
Long-term
associated
risk
people
up
decade
compared
no
treatment.
These
findings
highlight
role
sulfonylureas
inexpensive
readily
available
drugs
prevent
diabetes.
Язык: Английский
Novel Agents in the Management of Diabetes and Risk of Worsening Diabetic Retinopathy
Retina,
Год журнала:
2024,
Номер
44(11), С. 1851 - 1859
Опубликована: Авг. 16, 2024
Purpose:
Novel
therapies
for
diabetes
have
potent
effects
on
glycemic
control,
obesity,
and
cardiovascular
risk
reduction,
but
some,
including
the
popular
drug
semaglutide,
also
been
implicated
in
worsening
of
diabetic
retinopathy
(DR).
Given
ubiquity
these
new
agents,
understanding
risks
to
vision
is
important.
Here,
we
review
data
several
newly
available
agents
terms
systemic
efficacy
retinal
safety.
Methods:
Literature
review.
Results:
antihyperglycemic
treatments
include
incretin
mimetics
enhancers,
sodium-glucose
cotransporter
inhibitors,
long-acting
insulins,
insulin
delivery
systems.
All
improve
some
shown
reduce
major
outcomes.
In
a
pivotal
trial,
semaglutide
was
associated
with
approximately
75%
increased
DR
worsening.
The
novel
icodec,
formulated
once
weekly
dosing,
showed
over
daily
insulin.
No
other
recent
agent
worsening,
although
following
trials,
nearly
all
studies
excluded
patients
preexisting
DR.
Cases
were
rare
instances.
Dedicated
safety
are
currently
underway.
Conclusion:
For
most
being
considered
treatment
agent,
benefits
metabolic
health
very
likely
outweigh
potential
harms.
Although
true
unclear
because
their
come
from
secondary
end
points,
vulnerable
those
high-risk
DR,
poor
baseline
using
Язык: Английский
SGLT2 inhibitors and diabetic retinopathy: Insights from the management of nephropathy
Eye,
Год журнала:
2024,
Номер
unknown
Опубликована: Ноя. 12, 2024
Язык: Английский
Current Treatment Options for Diabetic Retinal Disease
Diabetes Technology & Therapeutics,
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 26, 2024
The
global
incidence
of
diabetes
is
rising
steadily
and
with
it
the
number
people
living
diabetic
retinal
disease
(DRD)
increasing.
Like
diabetes,
DRD
can
be
treated
but
not
cured.
In
response,
therapies
to
address
include
targeted
ocular
systemic
medications.
This
review
discusses
in
terms
current
screening
recommendations,
treatments,
considerations
related
those
future
drug
targets
trials
on
horizon.
discourse
at
all
members
care
team,
including
primary
providers,
optometrists,
ophthalmologists.
dynamic
landscape
retinopathy
treatment
promising
for
prevention
improvement
visually
significant
disease.
Язык: Английский